Recently published research from Business Monitor International, "Argentina Pharmaceuticals & Healthcare Report Q4 2014", is now available at Fast Market Research

Boston, MA -- (SBWire) -- 09/10/2014 --The Argentine economy is still reeling from the January 2014 currency devaluation. Soaring inflation and stringent drug pricing controls will continue to discourage investment and erode the growth of the country's pharmaceuticalmarket.More foreignpharmaceutical companies will cease their local operations, if the hostile business environment is worsened.

Headline Expenditure Projections:

Pharmaceuticals: ARS39.30bn (USD7.18 bn) in 2013 to ARS50.10bn (USD6.04bn) in 2014; +27.5% in local currency terms and -15.9% in US dollar terms. These figures have been revised downwards since Q314 due to a substantial deterioration in high frequency economic data.

Healthcare: ARS223.61bn (USD40.84bn) in 2013 to ARS280.22bn (USD33.76bn) in 2014; +25.3% in local currency terms and -17.3% in US dollar terms. These figures have also been revised downwards since Q314 due to new historical data.

View Full Report Details and Table of Contents

Risk/Reward Ratings: Argentina scores 54.5 in BMI's Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs), making it the ninth most attractive pharmaceutical market in America. Argentina's pharmaceutical market is expected to grow at double-digit rates through to 2017 in local currency terms, largely due to inflation.

Key Trends And Developments:

- In July 2014, the Argentine government planned to fine pharmaceutical companies up to ARS1mn (USD120,000), if they fail to roll back prescription drug prices to the levels requested on May 7.

- In July 2014, ANMAT approved Genzyme (Sanofi)'s Lemtrada (alemtuzumab) for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

- In June 2014, Switzerland-based biopharmaceutical company Ferring Pharmaceuticals divested its Argentinan affiliate Dupomar to the Argentina-based Investi for a consideration of USD4mn.

- In May 2014, Italian pharmaceutical company Menarini Laboratory decided to end its operations in Argentina.

BMI Economic View: Argentine real...

The Argentina Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Argentina Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Argentinian pharmaceutical and healthcare industry.

Key Benefits:

- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Argentina to test other views - a key input for successful budgeting and strategic business planning in the Argentinian pharmaceutical and healthcare market.

- Target business opportunities and risks in the Argentinian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Argentina.

- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage:

BMI Industry View & Industry SWOT:

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 800-844-8156

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Mexico Pharmaceuticals & Healthcare Report Q4 2014
- Thailand Pharmaceuticals & Healthcare Report Q4 2014
- Nigeria Pharmaceuticals & Healthcare Report Q4 2014
- Australia Pharmaceuticals & Healthcare Report Q4 2014
- Croatia Pharmaceuticals & Healthcare Report Q4 2014
- Hong Kong Pharmaceuticals & Healthcare Report Q4 2014
- Latvia Pharmaceuticals & Healthcare Report Q4 2014